| Mar 25 |
AIM ImmunoTech And 3 Other Stocks Under $3 Insiders Are Buying
|
| Mar 22 |
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
|
| Mar 15 |
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity
|
| Feb 29 |
AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update
|
| Feb 14 |
AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer
|
| Feb 8 |
AIM stock dips amid mixed results for post-COVID fatigue therapy
|
| Feb 8 |
AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
|
| Jan 24 |
AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer
|
| Jan 22 |
AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca’s Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer
|
| Jan 10 |
AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
|
